Please login to the form below
filgotinib
This page shows the latest filgotinib news and features for those working in and with pharma, biotech and healthcare.
Gilead’s Jyseleca is given a NICE recommendation for rheumatoid arthritis
Jyseleca (filgotinib) is an oral JAK inhibitor that can be administered as a monotherapy or used alongside another another common RA medicine called methotrexate. ... The FDA has expressed concerns regarding the overall benefit/risk profile of the
Latest news
-
Galapagos mid-stage trial failure raises concerns for Gilead deal
Following the disappointing results, Galapagos has lost out on the funds, with more pressure piled onto the other focal drug of the Gilead alliance – filgotinib. ... However, earlier this year the US Food and Drug Administration rejected Gilead’s
-
Lilly halts most clinical trials as coronavirus disruption continues
Biotech company Galapagos also announced last week that is has also postponed multiple studies of its experimental, Gilead-partnered drug filgotinib, which is currently in a range of late-stage studies
-
MorphoSys drops Novartis-partnered drug in eczema after phase 2 miss
AbbVie’s Rinvoq (upadacitinib), Gilead/Galapagos’ filgotinib and Pfizer’s abrocitinib.
-
Gilead promotes Andrew Dickinson to CFO, increased M&A expected
One of these potential blockbusters is JAK1 inhibitor filgotinib, which recently reported new, long-term phase 3 clinical data in rheumatoid arthritis.
-
Gilead poaches Genentech-exec Merdad Parsey for its new CMO
Company also files potential blockbuster filgotinib in Japan. As new CEO Daniel O’Day continues to overhaul Gilead’s top positions, Roche subsidiary Genentech’s Merdad Parsey has been appointed as ... Gilead has also bolstered its pipeline with the
More from news
Approximately 3 fully matching, plus 26 partially matching documents found.
Latest Intelligence
-
Setting up for success in a post-Brexit, post-pandemic Britain
Recently, Galapagos and Gilead Sciences received a positive NICE recommendation for Jyseleca (filgotinib) for use on the NHS which, for the first time, will support access to an advanced therapy for
-
Cortellis Drugs to Watch in 2020 report
Sales are projected at $1.589bn in 2024. 5. Filgotinib from Gilead/Galapagos is an oral JAK1 inhibitor in regulatory review in the US, EU and Japan for rheumatoid arthritis Overactivation ... If approved, filgotinib will be a late entrant into a very
-
20 for 2020 – Five pharma leaders to watch in 2020
filgotinib for rheumatoid arthritis. ... and filgotinib’s anticipated launch this year meets expectations in the increasingly competitive market for JAK inhibitors.
-
European biotech: a new generation of leaders emerges
is its experimental JAK1 inhibitor filgotinib for rheumatoid arthritis. ... This will include broader commercial rights in Europe for filgotinib, due to be filed later this year, setting up a 2020 launch.
-
Drug launches to watch in 2019
Lilly’s already-approved Olumiant (baricitinib) and Pfizer’s PF-04965842 are rivals for Abbvie’s upadacitinib, but Gilead and Galapagos’ filgotinib (an AbbVie cast-off) now looks like the biggest ... Likewise, upadacitinib will face competition
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Account Supervisor – Leading Healthcare Advertising Agency – New...
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
-
B2B media account director
-
Competitive salary
- Senior Medical Writer – Creative Healthcare Advertising – New Yo...
-
Highly Competitive Salary, Bonus &Benefits
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- First trial of a vaccine against Alzheimer’s launches
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- US government to pay $5.3bn for Pfizer‘s Paxlovid
- Roche to present new data for its drug Polivy at the American Society of Hematology’s annual meeting
- bluebird bio’s beti-cel accepted for priority review by FDA
- AstraZeneca officially opens new R&D facility in UK
- As HCPs Increasingly Expect Personalized Engagement, Pharmas Turn to Modular Intelligent Content. How Does This Work?
- COVID-19 vaccines against Omicron may be fast-tracked
- BMS’ new JAK inhibitor enters regulatory pathways
- Onyx Health Announces Two Top Appointments
- Omicron prompts global action
- Novo Nordisk growth takes a hit with China deal
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- Six ways to improve diversity in clinical trials
- Innovation in a digital context is not about technology – it’s about people
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- Novartis forms coronavirus alliance with life sciences companies
- Pfizer lifts 2021 guidance as sales of its BioNTech-partnered vaccine continue to climb
PMHub
Cuttsy + Cuttsy
How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...
Latest intelligence
- Webinar:
- Securing a future for telehealth with immersive market research insights...
- Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
- How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
- Six ways to improve diversity in clinical trials
- Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...
